Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins
about
Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causationPathogenesis of human immunodeficiency virus infectionAssays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytesNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophagesPolymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous.Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodiesPrincipal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane proteinSyncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent iStudy of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosisSequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cellsNative oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humansSelection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibodyBiological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies
P2860
Q24627627-1815B60D-E9D8-4E47-9B83-75BCDF3FC120Q24634681-C8316A32-6ACC-448C-B00C-CCFAEC86AD12Q28368240-86397946-9E5E-4271-8D44-B91875D59295Q30431941-9BD6C0FE-05C6-4764-B3B2-288DCC550210Q33560772-9FD8F90E-364D-4222-8B96-14A6163AD1D5Q33567984-461FCABC-7548-4455-AB77-106CB4A6A3C9Q33571605-F8B7C391-8E49-43B4-A040-85B896E73FD0Q33582665-5796733A-75B5-4176-A146-6F3000BFBAFAQ33720083-3A424986-11C9-4D2F-AA87-2ED231358343Q33822379-59F5F208-FCB6-4F47-98D1-5675C30384E0Q33880904-1B42246B-6E35-4FB0-8FA2-BCFB437F3019Q33927239-73C5EEC4-F202-49EF-BF17-89C6834A2709Q34097650-9992CA49-A321-45B3-AA69-A12CE2ED2FE6Q34101462-571FB6C1-B120-44FB-930B-F32E70D953A7Q34201595-059060A6-A813-42D8-95ED-B0554D025263Q34301897-17E26646-B191-4002-81A7-871647344298Q34313555-D1137A09-9594-42DF-8790-9189E9ADDEBAQ34332284-819E19C2-AB27-4320-AE66-7658BF69595EQ34338761-7B5924D7-4252-480F-9BAA-B5A1BD060036Q34750051-5BEB2898-F26E-472F-AE65-3054D110DC3CQ35113855-724C4718-3EE0-45BD-88BD-6614D2B851CFQ35144796-6A7553CF-5472-4DD4-BF30-66C92A8CF5DFQ35607085-70C4FF54-79DF-4D01-91CA-57DD74AA4C07Q35665722-CE5798F1-7A1A-4277-92C4-9FB33915DBE8Q35835028-825EF67F-7E37-49EC-9BE8-46764621AF20Q35852493-64A7E30F-3EEE-4230-95BB-F3EB5EE15AECQ35853761-3CFE6DDE-1C84-478F-8455-64E25CFC5BC1Q35879339-B9B849D2-E3EC-45CE-9C2E-0A468EE44E02Q35896178-08CE32CE-7161-4C18-8426-61651CCDC5A0Q36231815-640263A7-0DC5-42A4-B820-A9E5D62963E8Q36360966-F6801D5B-7913-413A-899B-ED7F1E3C5B51Q36633402-FEFA07F1-94C8-4B4E-95CA-E54D2B13CF89Q36634149-C224680D-022F-4769-B27B-7EB333E7B0B9Q36634341-43429E81-924E-4206-A996-EC27CD448754Q36641374-E630DA79-A1C7-425B-AC06-66C5CE333392Q36683893-B231412B-C632-4974-95E5-83870291BE50Q36684349-0738B272-BE84-44E6-B5DE-E9B7B39F8DDBQ36687562-C6525352-5B60-4C2F-97A8-703FFE2A6F54Q36687749-50EB46DA-88A0-47EA-8787-77749F3F28EBQ36690394-0B879E4F-4684-422B-A1E5-F491FE56952F
P2860
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins
description
1987 nî lūn-bûn
@nan
1987 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Human immunodeficiency virus n ...... on the envelope glycoproteins
@ast
Human immunodeficiency virus n ...... on the envelope glycoproteins
@en
type
label
Human immunodeficiency virus n ...... on the envelope glycoproteins
@ast
Human immunodeficiency virus n ...... on the envelope glycoproteins
@en
prefLabel
Human immunodeficiency virus n ...... on the envelope glycoproteins
@ast
Human immunodeficiency virus n ...... on the envelope glycoproteins
@en
P2093
P2860
P1433
P1476
Human immunodeficiency virus n ...... on the envelope glycoproteins
@en
P2093
M G Sarngadharan
M S Hirsch
R C Kennedy
R T Schooley
P2860
P304
P407
P577
1987-06-01T00:00:00Z